Profiling Gene Regulation Through Epigenomic Technologies

Key article takeaways

• Epigenomics reveals dynamic layers shaping cellular identity beyond genetics and transcriptomics.
• Core methods: DNA methylation (bisulfite/enzymatic), histone ChIP-seq, chromatin ATAC-seq/DNase-seq.
• Tradeoffs: Bisulfite damages DNA; ChIP-seq needs quality antibodies and high input.
• Advances: Enzymatic methylation sequencing, EpigenTek's CUT&RUN/CUT&LUNCH, single-cell atlases like Cao lab's EpiAge.
• Clinical use: Methylation/chromatin signatures for tumors, therapy prediction, aging studies.

Genomics and transcriptomics provide critical insight into the genetic underpinnings of disease. Although these methods remain important, research questions are shifting toward understanding regulatory mechanisms that shape how genes respond to environmental and cellular signals. Indeed, a suite of epigenomic profiling methods has emerged to gain a clearer understanding of when and how gene expression is regulated. As Michael Spelios, Ph.D., scientist at EpigenTek, explains, “While genetics defines potential and transcriptomics captures outcomes, epigenomics reveals the dynamic regulatory layers that determine cellular identity and functional state.”

This article highlights current epigenomic profiling methods and includes perspectives from industry leaders on recent technological advances and the expansion of epigenomic profiling in diverse research and clinical settings.

Core epigenomic profiling methods and considerations

Several established technologies are used to interrogate the major regulatory layers governing gene activity. These approaches profile key epigenetic features including DNA methylation, histone modifications, and chromatin accessibility. Given the variety of available methods, Spelios notes that “method choice should depend on the biological question and the stability of the regulatory feature being studied.”

DNA methylation profiling

DNA methylation is one of the most stable epigenetic regulatory marks and plays an important role in cellular identity, genomic imprinting, and tumor classification. Bisulfite sequencing remains widely used for mapping cytosine methylation across the genome. However, Spelios notes an important tradeoff: “Researchers must decide between bisulfite-based methods, which are well established but can damage DNA, and enzymatic alternatives that preserve DNA integrity.”

Histone modification profiling

To assess chromatin regulatory states, researchers traditionally use ChIP-seq, which provides high-resolution, genome-wide mapping of histone modifications and chromatin states associated with transcriptional activation or repression. Importantly, Spelios emphasizes that antibody quality and background noise, along with relatively large input requirements and careful experimental optimization, remain significant challenges for researchers using ChIP-seq.

Chromatin accessibility profiling

Chromatin accessibility assays such as ATAC-seq (and earlier methods like DNase-seq) are widely used to identify genome-wide regulatory elements and regions of open chromatin. These approaches are particularly useful for identifying regulatory elements such as promoters and enhancers and for studying how transcription factor binding landscapes change during disease progression.

Recent advances in epigenomics

Given the wide range of available techniques, Spelios highlights the importance of experimental design and integration: “Researchers should also consider sample input, cell heterogeneity, resolution needs, and whether locus-specific, genome-wide, or quantitative global analysis is required. Increasingly, integrating multiple epigenomic layers provides the most comprehensive view—linking DNA methylation stability, histone modification context, and chromatin accessibility into a unified regulatory model.”

Nevertheless, current research questions require higher resolution, greater sensitivity, and more robust analyses. Spelios describes advances in enzymatic methylation sequencing that improve detection of methylation and demethylation marks while preserving DNA integrity. Other developments include the growing adoption of targeted nuclease-based methods alongside conventional ChIP-seq. Spelios highlights EpigenTek’s CUT&RUN and CUT&LUNCH platforms, which improve signal-to-noise ratios while lowering input requirements for DNA, RNA, and chromatin samples. He also notes a shift toward streamlined kit-based workflows that reduce sample loss and technical variability, which is particularly important for studies involving rare cell populations or limited clinical specimens.

Large-scale single-cell epigenomic studies are also becoming feasible. For example, recent work from Junyue Cao’s laboratory at Rockefeller University generated a single-cell chromatin accessibility atlas across multiple tissues, demonstrating how regulatory programs shift across cell types during aging and highlighting the growing importance of epigenomic approaches for studying dynamic cellular responses.

Using EasySci-ATAC, an optimized single-cell ATAC-seq platform, the Cao lab profiled chromatin accessibility in more than 10 million nuclei across 21 mouse tissue types spanning multiple age groups. Their work identified approximately 1.3 million candidate cis-regulatory elements and revealed cell type–specific regulatory programs across hundreds of major cell types and nearly 2,000 subtypes. Beyond cataloging regulatory elements, the study also uncovered aging-associated chromatin reprogramming, shifts in cell population dynamics across tissues, and sex-specific chromatin states, illustrating how large-scale single-cell epigenomic profiling can link regulatory landscape changes to organism-level biological processes such as aging. These data can be explored freely here.

Epigenomic profiling and clinical applications

In parallel with the refinement of epigenomic technologies in basic research, emerging epigenomic signatures are beginning to inform our understanding of disease pathology and therapeutic response. Spelios notes, “5mC DNA and m6A RNA methylation signatures are used in tumor classification research and are under investigation in metabolic, cardiovascular, autoimmune, aging-related, and neurodegenerative disorders. Chromatin accessibility and histone-based signatures are being evaluated as predictors of therapeutic response, particularly in oncology and immunology. Improved low-input workflows and reduced-background chromatin profiling have increased compatibility with clinical and heterogeneous samples.”

As demonstrated by work from the Cao lab, large-scale epigenomic atlases are also helping researchers understand how regulatory changes contribute to aging and disease progression across tissues, highlighting the growing translational potential of epigenomic profiling in precision medicine and disease pathology.